📰 Valuating News
Page 13 - Valuating News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Valuating. Real-time updates on events, politics, business and more.
August 3, 2022
At the primary analysis, the trial did not meet its primary endpoint of overall survival (OS) The safety profile was consistent with previously reported studies of Onivyde (irinotecan liposomal
July 13, 2022
Humanigen, Inc. has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus... | July 13, 2022
July 12, 2022
The U.S. Navy recently installed its first 3D printer aboard one of its vessels in a program designed to test the capabilities of the technology and i...
July 8, 2022
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer ROCKVILLE, MD, July 08, 2022 --... | July 8, 2022
July 5, 2022
Salt Lake City, Utah--(Newsfile Corp. - July 5, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced enrolling the first patient as a part of a Phase 2 study
June 28, 2022
Nabiximols oromucosal spray continues to be evaluated in ongoing clinical trials in multiple sclerosis spasticity DUBLIN, June 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq:
June 9, 2022
-- First-in-human Phase 1/2a trial evaluating the proprietary deuterated psilocybin analog CYB003 expected to begin in mid-2022 -- ... | June 9, 2022
June 3, 2022
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric... | June 3, 2022
June 2, 2022
Data describe rapid, safe and robust microbiome engraftment1 of MaaT033 in the gut of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome undergoing intensive chemotherapy
June 2, 2022
60-patient enrollment target met plus 12% over-enrollment; top-line Phase 2a results expected to be presented during the European Sleep Research Society Congress in September 2022Nearly 90% of patients